Literature DB >> 10744204

A randomized, comparative study of fluorometholone 0.2% and fluorometholone 0.1% acetate after photorefractive keratectomy.

M Vetrugno1, G M Quaranta, A Maino, L Cardia.   

Abstract

PURPOSE: To compare the efficacy and tolerance of fluorometholone 0.1% acetate and fluorometholone 0.2% eyedrops in the postoperative management of photorefractive keratectomy (PRK).
METHODS: A randomised single-blind comparative study was performed on two groups of 30 patients who underwent myopic PRK. The first group was given fluorometholone 0.1% acetate and the second fluorometholone 0.2%. Uncorrected and best corrected visual acuity, haze, IOP and local tolerance were evaluated. Statistical analysis was done using parametric and non-parametric tests.
RESULTS: Visual acuity did not differ in the two groups; both were homogeneous as far as refractive error and haze were concerned. Three patients (10%) treated with fluorometholone 0.2% and two patients (6.6%) with fluorometholone 0.1% acetate developed ocular hypertension, but this was not statistically significant.
CONCLUSIONS: Fluorometholone 0.1% acetate was effective on inflammation after PRK, with the same efficacy as fluorometholone 0.2%.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744204     DOI: 10.1177/112067210001000107

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  2 in total

1.  Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?

Authors:  Uwe Pleyer; Paul G Ursell; Paolo Rama
Journal:  Ophthalmol Ther       Date:  2013-09-17

2.  Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper.

Authors:  Mark D Mifflin; Brent S Betts; P Adam Frederick; Jason M Feuerman; Carlton R Fenzl; Majid Moshirfar; Brian Zaugg
Journal:  Clin Ophthalmol       Date:  2017-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.